Valuation: Precision Therapeutics Inc

Market Cap 102M 91.05M 84M 76.01M 142M 9.68B 144M 1B 400M 5.07B 381M 373M 16.05B P/E 2026 *
-5.04x
P/E 2027 * -79.7x
Enterprise Value 102M 91.05M 84M 76.01M 142M 9.68B 144M 1B 400M 5.07B 381M 373M 16.05B EV / Sales 2026 *
1.68x
EV / Sales 2027 * 0.24x
Free-Float
93.93%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision Therapeutics Inc

Manager TitleAgeSince
Chief Executive Officer 57 09/02/2026
Director of Finance/CFO - 16/04/2026
President - 01/04/2026
Director TitleAgeSince
Director/Board Member 66 19/02/2020
Chairman 78 09/02/2026
Director/Board Member 60 09/07/2020
Change 5-day change 1-year change 3-year change Capi.($)
-7.56%-8.33% - - 104M
+0.34%+1.12%+34.75%+61.06% 64.14B
+0.98%+2.68%+12.25%+82.98% 55.53B
+1.75%+2.01%+13.30%+103.69% 53.03B
-1.43%-1.17%+26.27%+52.86% 45.99B
-0.48%-2.80%+18.01%+117.99% 42.45B
+0.82%+1.37%+227.94%+922.41% 40.45B
-0.26%-2.57%+12.55%+45.18% 32.25B
-2.07%+42.73%+103.77%+88.74% 34.47B
-0.62%-2.31%+22.31%-11.41% 24.23B
Average -0.86%+4.29%+52.35%+162.61% 43.62B
Weighted average by Cap. +0.05%+3.59%+49.24%+160.53%

Financials

2026 *2027 *
Net sales 60.4M 54.1M 49.91M 45.17M 84.46M 5.75B 85.82M 595M 238M 3.01B 227M 222M 9.53B 431M 386M 356M 323M 603M 41.07B 613M 4.25B 1.7B 21.49B 1.62B 1.58B 68.08B
Net income -41.4M -37.08M -34.21M -30.96M -57.89M -3.94B -58.83M -408M -163M -2.06B -155M -152M -6.53B -4.5M -4.03M -3.72M -3.37M -6.29M -429M -6.39M -44.36M -17.7M -224M -16.89M -16.53M -710M
Net Debt - -
Logo Precision Therapeutics Inc
Axe Compute Inc. is a virtual neocloud AI infrastructure platform. The Company provides customers with access to graphics processing unit (GPU) compute capacity for artificial intelligence (AI) and other high-performance computing workloads through a distributed network model, including infrastructure made available through the Aethir network. It also operates a digital asset treasury focused on the Aethir token (ATH), the native utility token of the Aethir network. Its segments include Compute Services and Treasury Management and Drug Discovery Services. Its Drug Discovery Services segment provides services that include the application of AI using its proprietary biobank of tumor samples, as well as creation of proprietary 3D culture models used in drug development. The Company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models through two offerings: Axe Compute Access and Axe Compute Build.
Employees
-